Precision Diagnosis and Treatment for Cancer

Research direction

We have established extensive, in-depth and long-term collaborations with many hospitals to conduct research on many cancer types including lung cancer, colorectal cancer and gynecological cancer. The research collaborations cover the screening of diagnostic biomarkers for early diagnosis of cancer, prognosis and efficacy evaluation, tumor heterogeneity molecular typing and other fields.

Eight technological advantages

  • Analysis of various types of tumor tissues and liquid biopsy

    Fresh surgical tissues

    FFPE samples

    Whole blood, pleural effusion, ascites, cerebrospinal fluid, etc.

  • Low inputs, comprehensive detection

    High recovery

    High purity ctDNA extraction technology

    Ensure that a small amount of samples can also yield high precision results

  • Highly specific

    Use of single-molecule tagging technology to effectively remove duplication

    Effectively reduce sequencing errors and PCR bias

    More accurate detection of low-frequency mutations

  • Professionally customized panels based on large clinical databases

    Based on treatment guidelines and research literatures

    Integrated with clinical therapies and prognosis information

    Various customized panels for pan-cancer or specific cancer types

  • Customized probe design

    High efficiency capture

    Using tiling probe method for high uniformity

    Capture comprehensive genetic profiles

  • Deep sequencing, reveal low-frequency variability

    Comprehensive assessment of the sequencing depth and itcorrelation with specificity and sensitivity

    Optimal depth of sequencing to ensure accuracy

  • Multi-platform verification of low-frequency mutations to ensure the accuracy of experimental results

    Low-frequency mutation was checked by droplet digital PCR (ddPCR) technology

    Verified by amplification refractory mutation system (ARMS) technology

  • Strict quality control

    Extensive negative and positive controls in the process of experiment and sequencing

    Synthetic spike-in mutation standards standards as internal control indexes


Genecast Biotechnoloty has carried out joint scientific research projects with more than 40 high-level hospitals and research institutes both in China and abroad, including Peking Union Medical College Hospital, Peking University Cancer Hospital, Chinese Academy of Medical Sciences Cancer Hospital, Shanghai Pulmonary Hospital, Chinese people People's Liberation Army General Hospital, Shanghai Jiao Tong University School of Medicine Ruijin Hospital, Fudan University Affiliated Tumor Hospital, Fudan University Affiliated Zhongshan Hospital, Huashan Hospital, West China Hospital, Sichuan Cancer Hospital, Zhongshan University Affiliated Tumor Hospital, Hebei Cancer Hospital, Shandong Province Cancer Hospital, Cancer Hospital of Heilongjiang Province.

10+ projects have been completed and over 100 projects in progress

Covering 40+ Triple A hospitals and cancer hospitals

Covering lung cancer, colon cancer, liver cancer, esophageal cancer, tongue cancer, pancreatic cancer, stomach cancer, cholangiocarcinoma, cervical cancer, bladder cancer, ovarian cancer, breast cancer and other cancers

Scientific Research Achievements

Published SCI articles

View details

Academic Communication

View details


View details

Software Copyrights

View details

Suite 903-908, HealthWork, No. 35 Huayuan North Rd., Haidian District, Beijing

Follow WeChat public accounts and learn More

Copyright © 2014-2019 臻和(北京)科技有限公司 Genecast Biotechnology Co., Ltd. Design by Bobrand